Source: Annual Congress 2007 - New treatments for asthma and COPD - experimental evidence
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Villetti, F. Bassani, M. Bergamaschi, P. T. Bolzoni, G. Amari, M. Delcanale, A. Rizzi, G. Rossoni, F. Berti, B. P. Imbimbo, R. Razzetti, R. Patacchini, M. Civelli (Parma, Milan, Italy). In vivo potent and long-lasting bronchodilator activity of muscarinic M₃ receptor antagonist CHF5407. Eur Respir J 2007; 30: Suppl. 51, 318

Member's Comments

No comment yet.

Related content which might interest you: In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist Source: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007 Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004 AZD3199: A potent and selective β2-adrenergic receptor agonist with rapid onset of action Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 Pharmacological activities of R-113281, a triple NK1 /NK2 /NK3 neurokinin receptor antagonist Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001 The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010 The antitussive effects of alpha7 (a7) nicotinic receptor agonists Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017 Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 The triple neurokinin receptor antagonist CS-003 inhibits neurokinin A (NKA)-induced bronchoconstriction in patients with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 415s Year: 2003 Modulation of cortical and respiratory activity by 5-HT2 receptor agonist in the rat Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep Year: 2008 Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020 A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance Source: Annual Congress 2007 - New drugs for COPD Year: 2007 Inhibition of cough reflex by D2 receptor agonism with Viozan™ (AR-C68397AA) Source: Eur Respir J 2001; 18: Suppl. 33, 32s Year: 2001 The novel dual D2 dopamine receptor, β2-adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001 Potentiation effect of insulin on M3 muscarinic receptor agonist induced airway smooth muscle contraction Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 Novel triple neurokinin receptors antagonist CS-003 strongly inhibits neurokinin related responses Source: Eur Respir J 2006; 28: Suppl. 50, 115s Year: 2006 Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Effects of a newly developed dual CysLT1 and CysLT2 receptor antagonist, ONO-RS-531, on antigen- and leukotriene D4-induced contractions of isolated human bronchi Source: Eur Respir J 2005; 26: Suppl. 49, 214s Year: 2005 In vitro pharmacological characterization of the novel inhaled bronchodilator CHF6366 acting as dual muscarinic antagonist/ß2-agonist (MABA) Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Increased relaxation of immature airways to beta-2 agonists is related to the attenuated expression of postjunctional smooth muscle muscarinic M2 receptors Source: Annual Congress 2004 - Understanding the complexity of how airways are regulated Year: 2004